New Developments in Gut Health & its Relationship to Systemic Illness - Nov. 16 - 18, 2012 - Planet Hollywood Resort & Casino - Las Vegas
Inflammatory bowel disease (IBD) is one of the five most prevalent gastrointestinal disease burdens in the United States, with an overall health care cost of more than $1.7 billion. This chronic condition is without a medical cure and commonly requires a lifetime of care. Each year in the United States, IBD accounts for more than $700,000 physician visits, 100,000 hospitalization, and disability in 119,000 patients. Over the long term, up to 75% of patients with Crohn's disease and 25% of those with ulcerative colitis will require surgery.
According to a recent article in the gastroenterology literature: Complementary and alternative medicine (CAM) is commonly used by the general public and by those suffering from chronic diseases including individuals with Crohn's disease (CD) and ulcerative colitis. This increase in patients' use of CAM has spurred interest in CAM among gastroenterologists and other physician's general knowledge of CAM efficacy in IBD is lacking and most physicians are unprepared to advise their patients about CAM or understand the application and appropriate use of CAM therapies in IBD or know the effect these therapies will have on conventional IBD therapies. According to multiple surveys published in the gastroenterology literature, patients using CAM report benefits that extend beyond simply improved disease control. Using CAM allows patients to exert a greater degree of control over their disease and its management than they are afforded by conventional medicine.
Small intestinal bacterial overgrowth (SIBO) is implicated in irritable bowel syndrome and is difficult to both diagnose and treat. This treatment challenge arises mainly because a specific algorithm for the treatment of irritable bowel syndrome (diarrhea subtype) does not exist, treatments are not equally effective in all patients, recommendations change, and new therapeutic options have recently become available. Reactions to dietary components have also been implicated in irritable bowel syndrome, but physician knowledge about optimal testing for and treatment of food-related allergic reactions are limited.
This activity will provide caregivers with information CAM interventions for irritable bowel disorder and irritable bowel syndrome: clinical nutrition, probiotics, integrative use of antibiotics, dietary therapy and hormonal interventions and will provide them with information to use in counseling patients about CAM interventions in inflammatory and irritable bowel syndrome, as well as other gastrointestinal conditions in which CAM therapies can be applied.
Register by the end of this week (Oct. 20) and receive Early Bird rates, which are $100 off. Get more information and register at: www.acamvegas.com.